Q-omics provides the consensus-scored CCDC9B profile across patient tissues and cancer cell-line models. CCDC9B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CCDC9B is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, CCDC9B protein abundance shows 22,989 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, THCA, and LSCC as cancer lineages where CCDC9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC9B survival associations across molecular data types. CCDC9B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC9B RNA expression–survival associations across cancer types. High CCDC9B expression shows unfavorable associations in BRCA, KIRC, OV and COAD, but favorable associations in ACC and ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CCDC9B RNA expression.
This table summarizes CCDC9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC9B shows lower tumor expression in THCA, KIRC, LUSC, HNSC, LUAD and UCEC. The THCA box plot shows higher CCDC9B RNA expression in normal versus tumor tissue (log2 FC = −1.544, t-test p < 0.001).
This table shows molecular features associated with CCDC9B in patient tissues and cancer cell lines. In patient samples, CCDC9B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SKIN.
